



Dear Colleagues,

In the run-up to the New Year, we are pleased to share with you the results of the outgoing 2014 and plans for 2015.



This year we have successfully completed the phase I clinical trial of the drug PAM-9 "Radio- and Chemoprotector, Adjuvant of Radio- and Chemotherapy" and are ready to proceed to phase II clinical trial.

Project PAM-8 "Compound for the Reproductive Function Recovery" has also successfully passed the phase Ib clinical trial. The second phase involving male patients is planned.



The registration dossier for PAM-1 "A Novel Compound with Antiviral Activity against Influenza and Other Acute Respiratory Infection Viruses" was filed to the Ministry of Health for gaining permission to carry out a phase I clinical trial.

On July 7<sup>th</sup> the Expert Council of the Agency for Strategic Initiatives (ASI), founded by the Government of the Russian Federation, announced the decision to support the project "Development and Marketing of Innovative Products - Immunochromatographic Test Strips for Diagnosis of the Myocardial Infarction on the basis of Heart-type Fatty Acid Binding Protein", implemented by the company "OFK Cardio" on-site of the biopharmaceutical alliance "Park of the Active Molecules". This project has earlier won the annual award established by Russian Vnesheconombank ("Bank for Development and Foreign Economic Affairs") for "The Best Project of Small and Medium-Sized Enterprises", beating 98 contenders. In December, the Foundation for Assistance to Small Innovative Enterprises in science and technology has supported our application "Commercialization of R&D and Technological Innovation with regard to Development and Manufacture of Immunochromatographic Tests for Rapid Diagnosis of Acute Myocardial Infarction", which is a continuation of the project supported by ASI.

The project PAM-12 "Memory Recovery and Consolidation Compound Efficient for Treatment of Alzheimer's Type Dementia" got the support of the Ministry of Industry and Trade for carrying out the preclinical research. Other two projects, PAM-3 "Oxygen Carrier" and PAM-14 "An Anticancer Compound" have successfully undergone the expert evaluation, and their support is expected next year.

A lot has been done for new molecules acquiring. Nine projects were added to our innovative portfolio. Molecules PAM-38 and PAM-43 showed high neuroprotective and cognitive-stimulating activity. The compounds PAM-42 and PAM-47 have been tested for ophthalmological use. These molecules are designed for glaucoma treatment. Preliminary functional studies have shown promising results. At the end of the year we began to study the molecule PAM-45 that might be effective as an anti-tumor, anti-metastatic and radiomodifying



Alliance of Competences "Park of Active Molecules"®

249031; 3, Kievskoye sh., Obninsk, Kaluga Region, Russia. Tel./fax: (48439) 6-58-79, tel: (48439) 9-72-58

E-mail: [project@pam-alliance.ru](mailto:project@pam-alliance.ru)

[www.pam-alliance.ru](http://www.pam-alliance.ru)



agent. Another molecule PAM-39 might be effective for treatment of leukemia.

Three molecules are at an early stage of primary expertise. These are: cryoprotective compound, wound healing molecule and compound with antibacterial action. Studies of these substances are scheduled to begin in January 2015.

The Regional Engineering Center, established in 2013 on the basis of the Alliance "Park of the Active Molecules", was retrofitted this year. The new equipment allows expanding the scope of ongoing research, laboratory, research and production activities.

2014 was marked by innovation in the management of intellectual property of the residents of AC "Park of the Active Molecules." Patent policy - innovative project strategy was elaborated for each molecule. The activities (not just purely "patent-related", but also biological, chemical research) are planned in accordance with the patent policy. This year PAM residents submitted new patent applications and were very active in operations under licenses.

The year was successful for Research and Education Center. In addition to fruitful collaboration with the Kaluga State University (KSU), this year a joint cooperation with the Moscow State University has started. In 2014, under the guidance of our experts, three KSU students and two students of the National Research Nuclear University took part in the regional competition "UMNIK-40". Three students received financial support. "UMNIK" contest winners included three employees of the company "Medbiopharm" (a PAM resident).

Summing up the results of 2014 we would like to point out that the outgoing year was fruitful and successful for us. We are entering the New Year with a rather impressive portfolio of new active molecules and with excellent results for the on-going projects! We were able to maintain our friendly team, and also to attract young qualified colleagues, including graduate students.

*We wish you and your colleagues the most expensive gifts under the Christmas tree: love, health, happiness, well-being, prosperity and new promising active molecules!*

*We hope that 2015 will become a year of mutually beneficial cooperation with the Alliance of Competence "Park of the Active Molecules."*

Sincerely yours,  
Rakhimdjan Roziev,  
Director NP AC "PAM"